$PCYC News Biotech hammered as ETFs down 5%, w
Post# of 94125
Biotech hammered as ETFs down 5%, while some stocks fall 10% 1:55 p.m. April 10, 2014 - Russ Britt
Is biotech caught in a bubble, and is it popping? 1:13 p.m. April 8, 2014 - Russ Britt
S&P 500’s slow-motion breakout attempt ‘rages on’ 12:43 p.m. Feb. 27, 2014 - Michael Ashbaugh
FDA approval of leukemia treatment boosts shares of Pharmacyclics 2:57 p.m. Feb. 12, 2014 - Russ Britt
Pharmacyclics shares soar after panel says cancer drug met goals 1:09 p.m. Jan. 7, 2014 - Russ Britt
Gilead, Acura stand out on up day for stocks, Quest tumbles 11:27 a.m. Oct. 10, 2013 - Russ Britt
Health care leads S&P as St. Jude gets some good news from FDA 11:49 a.m. Oct. 4, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 6:21 p.m. Sept. 26, 2013 - Russ Britt
Pharmacyclics shares jump after FDA accepts new cancer drug filing 12:09 p.m. Aug. 29, 2013 - Russ Britt
S&P 500 ventures to uncharted territory 12:21 p.m. July 18, 2013 - Michael Ashbaugh
Pharmacyclics seeks fast-track drug approval, makes double-digit gain 11:09 a.m. July 10, 2013 - Russ Britt
Onyx share surge lifts several boats in biotech harbor, including ETFs 11:33 a.m. July 1, 2013 - Russ Britt
Positives continue to build for the Nasdaq 1:31 p.m. June 4, 2013 - The Trading Deck
For the medium-term trader, setups galore 11:39 a.m. May 14, 2013 - The Trading Deck
After the close: Big gains for Pharmacyclics, Biogen, Warner 5:39 p.m. May 13, 2013 - Russ Britt
FDA gives 'breakthrough' designation to Merck drug 9:10 p.m. April 23, 2013 - MarketWatch.com
Quest Diagnostics shares climb on glowing words from Goldman 12:26 p.m. April 11, 2013 - Russ Britt
Nasdaq clues suggest more upward valuation 1:46 p.m. March 8, 2013 - The Trading Deck
Leading stocks strut their stuff 11:39 a.m. March 5, 2013 - The Trading Deck
The return of the European bogeyman 1:58 p.m. Feb. 26, 2013 - The Trading Deck
Undervalued Biotech Stocks Beat the Index 6:54 a.m. Today - Barrons.com
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog 5:15 p.m. July 28, 2014 - Zacks.com
Can the Rally in Pharmacyclics (PCYC) Shares Continue? - Tale of the Tape 8:37 a.m. July 24, 2014 - Zacks.com
7 Biotechnology Stocks to Buy Now 6:00 a.m. July 23, 2014 - InvestorPlace.com
Medivation Significantly Undervalued, With Xtandi Weeks Away From Prostate Cancer Label Expansion 2:06 p.m. July 21, 2014 - Seeking Alpha
Biotechs Have Their 'Irrational Exuberance' Moment: Time To Buy More? 10:40 a.m. July 21, 2014 - Seeking Alpha
4 Top Biotechs Expected to Beat Earnings Expectations 9:17 a.m. July 16, 2014 - 247WallSt.com
7 Biotechnology Stocks to Buy Now 6:30 a.m. July 16, 2014 - InvestorPlace.com
8 Biotechnology Stocks to Buy Now 5:45 a.m. July 9, 2014 - InvestorPlace.com
Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment 8:01 a.m. July 8, 2014 - Seeking Alpha
Pharmacyclics Inc. (PCYC): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 8:00 a.m. July 3, 2014 - Zacks.com
8 Biotechnology Stocks to Buy Now 6:15 a.m. July 2, 2014 - InvestorPlace.com
Individual Investor Portfolio Update: Diversifying For Growth 1:40 a.m. July 1, 2014 - Seeking Alpha
Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics 8:18 a.m. June 30, 2014 - benzinga.com
7 Biotechnology Stocks to Buy Now 6:30 a.m. June 25, 2014 - InvestorPlace.com
'Fast Money' Recap: A Mixed Bag for Housing 5:00 a.m. June 25, 2014 - TheStreet.com
Cramer's Mad Money - 9 Things To Watch In The Week Ahead (6/20/14) 5:10 a.m. June 22, 2014 - Seeking Alpha
Fire Up The Immuno-Oncology Powerhouses: John McCamant 5:39 p.m. June 19, 2014 - Seeking Alpha
7 Biotechnology Stocks to Buy Now 5:45 a.m. June 11, 2014 - InvestorPlace.com
Pharmacyclics' Imbruvica Under FDA Priority Review - Analyst Blog 6:45 p.m. June 10, 2014 - Zacks.com
Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 7:02 p.m. July 28, 2014 - PR Newswire - PRF
U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications 1:18 p.m. July 28, 2014 - PR Newswire - PRF
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) for Treatment of Two Blood Cancers 8:52 a.m. July 25, 2014 - PR Newswire - PRF
Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics 7:04 a.m. July 14, 2014 - PR Newswire - PRF
Critical Alerts For Intuitive Surgical, Estee Lauder, Dominos Pizza, Pharmacyclics, and Tata Motors Released By InvestorsObserver 9:31 a.m. July 2, 2014 - PR Newswire - PRF
Stock Watchout on Biotech Industry -- Research on Isis Pharma, Pharmacyclics, Amarin, and Prana Biotechnology 7:10 a.m. June 11, 2014 - PR Newswire - PRF
Supplemental New Drug Application for IMBRUVICA® Accepted by the U.S. FDA and Priority Review Granted 8:00 a.m. June 9, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases 8:05 a.m. May 31, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study 8:05 a.m. May 31, 2014 - PR Newswire - PRF
Milestone Payments, Clinical Trial Results, Technical Updates, and Earnings Results - Analyst Notes on Pharmacyclics, Isis, Novo Nordisk, Dr. Reddy's and Orexigen 5:10 a.m. May 29, 2014 - PR Newswire - PRF
Favorable Support, NDA Submission, Conference Schedule, Acquisition Update, and Executive Appointment - Analyst Notes on Allergan, Pfizer, Eli Lilly, Forest and Pharmacyclics 7:20 a.m. May 27, 2014 - PR Newswire - PRF
Pharmacyclics appoints Gregory R. Wade to lead Business Development 8:00 a.m. May 20, 2014 - PR Newswire - PRF
Biotech Equities Coverage -- Research on Isis Pharma, Pharmacyclics, Prana Biotech, and United Therapeutics 11:29 a.m. May 19, 2014 - PR Newswire - PRF
Study Results, Analyst Meetings, Upcoming Events, Financial Results, and Welfare Initiatives - Analyst Notes on Pharmacyclics, Thermo Fisher Scientific, Endo, Humana and Aetna 8:00 a.m. May 19, 2014 - PR Newswire - PRF
FDA Approvals, Stock Price Updates, and Financial Results Release - Analyst Notes on Pfizer, Actavis, Pharmacyclics, Mallinckrodt and Salix Pharmaceuticals 7:40 a.m. May 16, 2014 - PR Newswire - PRF
Pharmacyclics Highlights Important New Data for IMBRUVICA® (ibrutinib) in B-Cell Malignancies 6:22 p.m. May 14, 2014 - PR Newswire - PRF
Pharmacyclics Reports First Quarter 2014 Results 8:00 a.m. May 2, 2014 - PR Newswire - PRF
Pharmacyclics Announces Date of Conference call to discuss Financial Results for First Quarter of 2014 10:45 a.m. April 25, 2014 - PR Newswire - PRF
Pre-market Equity Watch on the Health Care Sector -- Research on Isis Pharma, Pharmacyclics, Novo Nordisk, and Lannett 9:04 a.m. April 22, 2014 - PR Newswire - PRF
Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA™ in Chronic Lymphocytic Leukemia (CLL) at ASCO 11:45 a.m. April 21, 2014 - PR Newswire - PRF